Additionally, advancing our understanding of tonic TCR signaling on naïve CD8+T cells, along with the role of Nur77 in T cell responses, could offer new avenues for enhancing the efficacy of immunotherapies, which may lead to the development of more effective and targeted treatments for patients with ES‐SCLC and other malignancies. The gene discussed is CD8A; the disease is small cell lung carcinoma.